HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation.

Analyst Price Forecast Suggests 99.16% Upside

As of January 28, 2025, the average one-year price target for CRISPR Therapeutics is $82.83/share. The forecasts range from a low of $30.30 to a high of $281.40. The average price target represents an increase of 99.16% from its latest reported closing price of $41.59 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for CRISPR Therapeutics is 13,142MM, an increase of 6,379.35%. The projected annual non-GAAP EPS is -6.65.

What is the Fund Sentiment?

There are 575 funds or institutions reporting positions in CRISPR Therapeutics. This is an decrease of 50 owner(s) or 8.00% in the last quarter. Average portfolio weight of all funds dedicated to CRSP is 0.24%, an increase of 8.90%. Total shares owned by institutions increased in the last three months by 0.51% to 76,426K shares. The put/call ratio of CRSP is 0.34, indicating a bullish outlook.

What are Other Shareholders Doing?

Capital International Investors holds 7,927K shares representing 9.29% ownership of the company. In its prior filing, the firm reported owning 7,865K shares , representing an increase of 0.78%. The firm decreased its portfolio allocation in CRSP by 18.27% over the last quarter.

ARK Investment Management holds 7,499K shares representing 8.79% ownership of the company. In its prior filing, the firm reported owning 7,779K shares , representing a decrease of 3.73%. The firm decreased its portfolio allocation in CRSP by 13.58% over the last quarter.

ARKK - ARK Innovation ETF holds 5,416K shares representing 6.34% ownership of the company. In its prior filing, the firm reported owning 5,280K shares , representing an increase of 2.51%. The firm decreased its portfolio allocation in CRSP by 8.98% over the last quarter.

ANWPX - NEW PERSPECTIVE FUND holds 4,691K shares representing 5.50% ownership of the company. No change in the last quarter.

Nikko Asset Management Americas holds 2,967K shares representing 3.48% ownership of the company. In its prior filing, the firm reported owning 3,152K shares , representing a decrease of 6.21%. The firm decreased its portfolio allocation in CRSP by 19.54% over the last quarter.

CRISPR Therapeutics Background Information
(This description is provided by the company.)

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.